Article
Mechanisms for isoniazid action and resistance.
Novartis Foundation symposium - 1 Jan 1998
Miesel L, Rozwarski D A, Sacchettini J C, Jacobs W R
Abstract excerpt
Isoniazid is the most widely used antituberculosis drug. Genetic studies in Mycobacterium smegmatis identified the inhA-encoded, NADH-dependent enoyl acyl carrier protein reductase as the primary target for this drug. A reactive form of isoniazid inhibits InhA by reacting with the NAD(H) cofactor bound to the enzyme active site forming a covalent adduct (isonicotinic acyl NADH) that is apt to bind with high...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.